Adverse reactions to Zn1-24 ACTH therapy associated with specific cellular immunity.
Lymphocyte transformation to 1-24ACTH, as assessed by the incorporation of tritiated thymidine, has been demonstrated to be associated with severe adverse reactions occurring in patients receiving a Zn-linked 1-24ACTH preparation (Tetra cosactrin depot, 'Synacthen'). Antibodies measured with an isotope-binding assay occurred commonly in all patients receiving therapy and did not correlate with adverse reactions. Lymphocyte transformation with the 1-24ACTH polypeptide, a part of the naturally occurring ACTH molecule, has not been previously recorded. The significance of antibodies and cell-mediated immunity to this polypeptide hormone is discussed.
D000324:Adrenocorticotropic Hormone / Q000031:analogs & derivatives*; D000328:Adult; D000906:Antibodies / Q000032:analysis; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D001249:Asthma / Q000188:drug therapy; D002648:Child; D003366:Cosyntropin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004342:Drug Hypersensitivity; D005260:Female; D006801:Humans; D007111:Immunity, Cellular; D008213:Lymphocyte Activation; D008297:Male; D008875:Middle Aged; D015032:Zinc / Q000009:adverse effects
D000906:Antibodies; D003366:Cosyntropin; D000324:Adrenocorticotropic Hormone; D015032:Zinc